Isomorphic Labs Valued at $40 Billion as AI Drug Discovery Nears Clinic

Isomorphic Labs, the AI-powered drug discovery subsidiary spun from Alphabet's Google DeepMind, is in early-stage funding talks that would value the company at a minimum of $40 billion, with valuations potentially reaching $50 billion, according to people familiar with the matter. The London-based company, founded in 2021 under AI pioneer Demis Hassabis's leadership, has become one of the world's most heavily capitalized life sciences startups in just five years, reflecting surging investor confidence in artificial intelligence's ability to accelerate drug development.